Research provided by covering analysts may contain projections on where they see a certain stock going in the future. Sell-side research reports may contain estimates and share recommendations as well. Monitoring analyst opinions on a company they track might assist investors with gathering vital information. Out of the 6 covering analysts offering stock ratings for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), 7 have shares pegged a Strong Buy while 0 analysts have the stock marked a Buy. 0 analysts have the stock rated Hold, and 0 are giving a Sell recommendation.
These recommendations can be transferred to a standard scale from 1 to 5. Combining all of the ratings, the current consensus is sitting at 1. A rating of 1 would be equivalent to a Strong Buy, and a rating of 5 would indicate a Strong Sell rating.
Let’s take a look at analyst target price estimates on the stock. The 6 analysts offering target price estimates on shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) have set a consensus target of $39.166 on shares. The standard deviation of all the estimates is currently $6.585. Target price projections may differ from analyst to analyst. The lowest price target is presently $34 and the analyst with the most aggressive opinion sees the stock going to $52.
The quarterly company earnings release is usually highly anticipated. Each quarter, investors and analysts wait to see the earnings numbers when they are posted for the public. The company is slated to next publish earnings on or around 2017-08-03. The current Wall Street consensus is expecting Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) to report EPS of $-0.89 for the quarter. Analysts often update their models during the time leading up to earnings. The sentiment direction can be an important factor when trying to gauge where the Street sees the stock moving. Compared to the same quarter last year, the company reported earnings per share of $-1.69. After the most recent period, the company reported quarterly EPS of $-1.14 against the Zacks Research consensus estimate of $-1.2. This created a surprise factor of 5% or a numerical difference of $0.06.
This article is for informational purposes only. The author does not have any position in the stock mentioned and in no way is recommending to Buy or Sell Paratek Pharmaceuticals, Inc. .